PLZF is a new substrate of CRBN with thalidomide and 5-hydroxythalidomide
S. Yamanaka, H. Murai, D. Saito, G. Abe, E. Tokunaga, T. Iwasaki, H. Takahashi, H. Takeda, T. Suzuki, N. Shibata, K. Tamura, T. Sawasaki
The paper identifies PLZF as a CRBN substrate degraded by thalidomide and 5-hydroxythalidomide, linking it to teratogenesis.
bioRxiv · Feb 28, 2020Pharmacology & Toxicology